00:24:46 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-02-07 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-06-08 Årsstämma 2023
2023-05-31 Kvartalsrapport 2023-Q1
2023-05-10 Ordinarie utdelning IDOGEN 0.00 SEK
2023-02-24 Bokslutskommuniké 2022
2022-12-13 Extra Bolagsstämma 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-05 Ordinarie utdelning IDOGEN 0.00 SEK
2022-05-04 Kvartalsrapport 2022-Q1
2022-05-04 Årsstämma 2022
2022-01-19 Bokslutskommuniké 2021
2021-10-26 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-05-12 Ordinarie utdelning IDOGEN 0.00 SEK
2021-05-12 Kvartalsrapport 2021-Q1
2021-05-11 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-11-04 Extra Bolagsstämma 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-08-25 Kvartalsrapport 2020-Q2
2020-05-27 Split IDOGEN 10:1
2020-05-13 Ordinarie utdelning IDOGEN 0.00 SEK
2020-05-12 Kvartalsrapport 2020-Q1
2020-05-12 Årsstämma 2020
2020-01-29 Bokslutskommuniké 2019
2019-10-22 Kvartalsrapport 2019-Q3
2019-08-20 Kvartalsrapport 2019-Q2
2019-06-26 Ordinarie utdelning IDOGEN 0.00 SEK
2019-06-25 Årsstämma 2019
2019-04-29 Kvartalsrapport 2019-Q1
2019-02-06 Bokslutskommuniké 2018
2018-10-23 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-04-25 Ordinarie utdelning IDOGEN 0.00 SEK
2018-04-24 Årsstämma 2018
2018-04-24 Kvartalsrapport 2018-Q1
2018-02-06 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-08-30 Kvartalsrapport 2017-Q2
2017-05-18 Ordinarie utdelning IDOGEN 0.00 SEK
2017-05-17 Årsstämma 2017
2017-04-24 Kvartalsrapport 2017-Q1
2017-02-15 Bokslutskommuniké 2016
2016-11-11 Kvartalsrapport 2016-Q3
2016-08-26 Kvartalsrapport 2016-Q2
2016-04-26 Kvartalsrapport 2016-Q1
2016-04-26 Årsstämma 2016
2016-02-18 Ordinarie utdelning IDOGEN 0.00 SEK
2016-02-17 Bokslutskommuniké 2015
2015-10-29 Kvartalsrapport 2015-Q3
2015-08-27 Kvartalsrapport 2015-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Idogen är verksamma inom bioteknik. Bolagets affärsinriktning är att utveckla vaccinkandidater för behandling av sjukdomar som negativt påverkar immunförsvaret. Vaccinen avses att användas i de fall där det uppkommit autoimmuna sjukdomar och efter organavstötning, särskilt vid de fall där de bildats antikroppar mot intagningen av patientens ordinarie läkemedel. Bolaget grundades under 2008 och har sitt huvudkontor i Lund.
2022-08-25 08:02:00

Idogen AB's interim report for January to June 2022 is available on the company's website https://idogen.com/en/investors/financial-reports/

Second quarter (April-June 2022)
  • Other operating income amounted to KSEK 159 (1,731)

  • Operating loss was KSEK -11,157 (-9 541)

  • Loss for the quarter totalled KSEK -11,196 (-9,604)

  • Cash flow from operating activities was KSEK -10,172 (-6,135)

  • Loss per share before dilution was SEK -0.15 (-0.53). Loss per share after dilution was SEK -0.15 (-0.53)

Period (January-June 2022)
  • Other operating income amounted to KSEK 159 (3,409)

  • Operating loss was KSEK -21,869 (-20,164)

  • Loss for the quarter totalled KSEK -21,888 (-20,135)

  • Cash flow from operating activities was KSEK -28,232 (-16,087)

  • Loss per share before dilution was SEK -0.38 (-1,10). Loss per share after dilution was SEK -0.38 (-1,10)

Significant events in the second quarter
  • Idogen receives approval from the Norwegian Medicines Agency, NoMA, for a clinical phase 1/2a study
with the IDO 8 program.
  • Idogen strengthens the organization with key competencies for the clinical development phase.
Significant events in the period
  • Idogen submits an application for clinical trial with IDO 8 to the Norwegian Medicines Agency, NoMA.

  • Idogens presented the company's tolerogenic cell therapy platform at the 5th Antigen-Specific Immune Tolerance Summit.

  • Idogen enters into an agreement with Vator Securities AB regarding the assignment as Certified Adviser from 15 May.

  • Idogen's rights issue raise MSEK 41 after issue costs.

  • Idogen receives approval from the Swedish Medical Products Agency to start its clinical phase 1/2a study for IDO 8.

Significant events after the end of the period
  • Idogen brings together scientific advisors at the ISTH 2022 scientific conference in London.

  • Idogen's CEO Anders Karlsson leaves for a new assignment and Christina Herder is appointed acting CEO

  • Idogen convene major owners for election to Board

  • Idogen invite to an Extraordinary General Shareholder Meeting on September 6

  • No other significant events occurred after the end of the period that affected the results or financial position.

For further information, please contact:

Anders Karlsson, CEO, Idogen AB

Phone: +46 (0)70918 00 10

Email: anders.karlsson@idogen.com

Certified Adviser:
Vator Securities AB, Kungsgatan 34, SE-111 35 Stockholm,

Email: ca@vatorsec.se.

Tel: +46 (0)8-580 065 99

The information was submitted for publication, through the agency of the contact persons set out above, on August 25, 2022 at 08:02 CET.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.